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Abstract
The Notch signalling pathway is one of the main regulators of endothelial biology. In the last 20 years the critical function of 
Notch has been uncovered in the context of angiogenesis, participating in tip-stalk specification, arterial-venous differentia-
tion, vessel stabilization, and maturation processes. Importantly, pharmacological compounds targeting distinct members 
of the Notch signalling pathway have been used in the clinics for cancer therapy. However, the underlying mechanisms 
that support the variety of outcomes triggered by Notch in apparently opposite contexts such as angiogenesis and vascular 
homeostasis remain unknown. In recent years, advances in -omics technologies together with mosaic analysis and high 
molecular, cellular and temporal resolution studies have allowed a better understanding of the mechanisms driven by the 
Notch signalling pathway in different endothelial contexts. In this review we will focus on the main findings that revisit the 
role of Notch signalling in vascular biology. We will also discuss potential future directions and technologies that will shed 
light on the puzzling role of Notch during endothelial growth and homeostasis. Addressing these open questions may allow 
the improvement and development of therapeutic strategies based on modulation of the Notch signalling pathway.
Keywords Notch signalling · Endothelial cells · Angiogenesis · Vascular homeostasis · Arterial-venous specification
Introduction
Our body contains an extensive tubular network of blood 
vessels lined by a monolayer of endothelial cells (ECs) 
that arose during evolution in order to carry oxygen and 
nutrients to distant tissues and organs in the body [1]. The 
first vascular structures are assembled by coalescence of 
endothelial progenitor cells and in situ differentiation, a 
process known as vasculogenesis, which gives rise to the 
first arteries (dorsal aorta), veins and the primitive vascular 
plexus [2]. This primary vessel network is later expanded 
through the process of angiogenesis that requires an equi-
librium between endothelial cell proliferation, sprouting 
and migration in order to form new blood vessels and at 
the same time maintain the function of pre-existing ones. 
Angiogenesis involves not only the formation of new blood 
vessels, but also the remodelling and arteriovenous differen-
tiation of pre-existing blood vessels, in order to maintain an 
effective vascular function that fulfils the metabolic needs 
of the surrounding tissues. This involves a constant cross-
talk between developing or remodelling blood vessels and 
the surrounding tissues. Over time, a given tissue vascular 
bed will adopt different architectures to match the evolving 
demands of the surrounding tissue. For this reason, vascu-
lar development and angiogenesis is only completed once 
the surrounding tissue stops growing. In a mature or adult 
organism, vessels acquire a quiescent or dormant state, but 
they still retain important homeostatic functions and can 
be reactivated under certain physiological or pathological 
stimuli. Given their ubiquitous organ distribution and their 
general relevance for tissue function, growth, healing and 
regeneration, blood vessels play a very important role in 
the pathogenesis of most diseases [3]. Research in the last 
decades revealed the existence of several molecular and cel-
lular mechanisms involved in the regulation of angiogenesis 
and vascular homeostasis. Some of these mechanisms are 
important for every aspect of endothelial biology, whereas 
others have more specific or accessory functions. Similarly 
to vascular endothelial growth factor (VEGF) signalling, the 
Notch signalling pathway is among the top regulators of 
 * Rui Benedito 
 rui.benedito@cnic.es
1 Molecular Genetics of Angiogenesis Group, Centro Nacional 
de Investigaciones Cardiovasculares (CNIC), Melchor 
Fernández Almagro 3, 28029 Madrid, Spain


































































    








Journal : Large 10456 Article No : 9793 Pages : 14 MS Code : 9793 Dispatch : 24-5-2021
 Angiogenesis
1 3
vascular biology. Here we provide an updated review on the 
role of Notch in endothelial biology.
Notch signalling and its cell context dependency
In mammals, there are four distinct Notch receptors (Notch1-
4) that can interact with five different ligands: three of the 
Delta-like ligand (Dll) family (Dll1, Dll3, Dll4) and two of 
the Jagged family (Jag1 and Jag2). Both ligands and recep-
tors are transmembrane proteins with large extracellular 
domains formed by epidermal growth factor (EGF)-like 
repeats, through which they interact with each other. The 
activation of the pathway is triggered when Notch receptors 
interact with transmembrane ligands provided by neigh-
bouring cells [4, 5]. This binding promotes two proteolytic 
cleavage events in the Notch receptor. The first cleavage is 
performed by ADAM-family metalloproteases. The sec-
ond cleavage, which is mediated by a γ-secretase, releases 
the Notch intracellular domain (Notch ICD or NICD) of 
the receptor. Then, the cleaved NICD translocates to the 
nucleus, where it binds the transcription factor RBPJk and 
recruits co-activators such as Mastermind-like (MAML). 
This transcriptional complex is able to bind several pro-
moters containing Rbpjk binding sites, including canoni-
cal Notch target genes, such as Hes/Hey encoding basic 
helix-loop-helix (bHLH) transcriptional repressors [6]. The 
complexity in understanding the role of Notch in cell biol-
ogy stems from the fact that this apparently simple Notch 
signalling-transcriptional program varies greatly between 
different cell types, and also within a single-cell type it can 
vary significantly according to the genomic and transcrip-
tional status of the cell. This is because the effects of this 
transcriptional machinery are signalling dose-dependent and 
also because it interacts with a diverse repertoire of exist-
ing transcription factors and chromatin states in the cell [7]. 
Therefore, knowing the transcriptional programs elicited by 
Notch in blood cells, neurons, or epithelial cells, will not 
help us to understand how Notch controls the biology of 
endothelial cells. As a simple example, Notch activation in 
blood cells promotes Myc expression and cell proliferation, 
which can lead to leukemia [8], while in endothelial cells 
Notch overactivation blocks Myc expression and cell pro-
liferation [9]. Another example is that Notch activation in 
neurons mostly activates the canonical Hes genes, while in 
endothelial cells it mostly activates the canonical Hey genes.
Within endothelial cells, it is also becoming clear that 
Notch triggers completely different transcriptional programs 
in HUVECs vs HUAECs cultured in vitro [10]. In vivo there 
are also significant differences between the genetic programs 
controlled by Notch in growing coronary [9] and retina [11] 
vessels and even within the same growing retina vascular 
network, Notch has spatial and temporal-context-dependent 
roles on EC proliferation [11]. Future single-cell -omics 
studies will likely expand on this complexity and diversity 
of Notch functions in single endothelial cells of different 
organs during development and disease.
Functional relevance of distinct Notch signalling 
members
Most endothelial cells express mainly the receptors Notch1 
and Notch4, and the ligands Dll4 and Jag1, even though all 
other receptors and ligands are also expressed in endothe-
lial cells [12–15]. Targeted disruption of different Notch 
components leads to early embryonic lethality due to severe 
vascular development defects. Dll4 has been shown to be 
the most important Notch ligand for early vascular develop-
ment and angiogenesis. Like the VEGF ligand, its full dose 
is needed for vascular development. Most mouse embryos 
lacking a single Dll4 allele are haploinsufficient [16, 17] and 
die in utero between E9.5-E10.5 with vascular development 
defects similar to those in Dll4KO embryos. Full loss-of-
function mutants for Jag1 [18] and Dll1 [19] show signifi-
cantly milder vascular development defects, and die at E10.5 
and E12, respectively. On the other hand, Jag2 mutants die 
at birth, but this is due to craniofacial morphogenesis defects 
[20]. These studies revealed the relative importance of the 
different ligands for embryonic angiogenesis, but we still 
do not know well how the different ligands compensate for 
each other and how they regulate Notch signalling in other 
organ vascular beds, in adult blood vessels, or in disease. 
This is particularly relevant since there are now blocking 
antibodies against each of these ligands [21–24], and a better 
understanding of their different functions in physiology and 
disease could open new therapeutic options.
Similarly to the ligands, we also have now blocking anti-
bodies against the different Notch receptors [25, 26] but we 
still know little about the functions of the different Notch 
receptors in endothelial biology, with the exception of stud-
ies in early mouse embryos. These studies clearly indicated 
that Notch1 is the most important receptor for early angio-
genesis, since Notch1KO or Notch1floxed−Tie2−Cre embryos die 
at E9.5 with severe vascular development defects, similarly 
to RbpjKO embryos [27–29]. However, it was also shown 
that at least Notch4 can partially compensate for Notch1 
loss [28], and perhaps Notch2 and Notch3, which are weakly 
expressed in endothelial cells, may also have an important 
role in endothelial cells when Notch1 and Notch4 functions 
are lost. It is interesting to note that most studies in the field 
have used Rbpjfloxed mice to understand the consequence of 
disrupting all Notch receptor signalling [17, 30–32], but 
Rbpj is not a transcription factor specific to Notch signal-
ling and may also have Notch-independent roles. In fact, 
several studies have revealed significant differences between 
Rbpj and Notch loss-of-function studies in cardiomyocytes, 
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In endothelial cells, it is currently believed that loss of 
Rbpj generally phenocopies the use of γ-secretase inhibi-
tors or Notch1/Dll4 loss-of-function [11, 16, 17, 21, 22, 28, 
36–40] but a thorough phenotypic and RNAseq comparison 
is needed to fully determine this. The existent higher resolu-
tion loss-of-function retina angiogenesis data suggest that 
there are significant phenotypic differences between Dll4/
Notch1/Rbpj mutants [11, 36, 40] being that the increase in 
vascular density and lack of arterialization after Dll4 dele-
tion is more pronounced than after Notch1 or Rbpj deletion. 
However, these differences may be because it is easier to 
delete Dll4 than Notch1 and Rbpj in retina vessels, or the 
faster turnover of Dll4 in comparison to Rbpj protein. So far 
not a single study compared the simultaneous deletion of 
the four Notch receptors to the deletion of Rbpj, something 
difficult to achieve technically. It has been much easier to 
combine and induce the deletion of two Rbpj floxed alleles, 
than of eight floxed alleles corresponding to the four Notch 
receptors, especially because two of them are located in the 
same chromosome (Notch3 and Notch4) and thus cannot 
be combined. The alternative of comparing the effects of 
Rbpj deletion with general γ-secretase inhibitors (to block all 
Notch receptors) is also not ideal, since the former represents 
full genetic deletion, and the latter an incomplete loss of 
Notch signalling. Our current assumption that Rbpj deletion 
mimics the loss of all Notch signalling in endothelial cells 
may be wrong in many cases and should be further tested. 
We will also need to take this into account if we intend to 
use RbpjiLOF data to predict the consequence of Notch block-
ers/inhibitors in the clinics.
Role of Notch in arterial specification
After vasculogenesis, the first and primitive capillary plexus 
is remodelled into a hierarchical network of vessels contain-
ing arteries and veins. Arteries are specialized in delivering 
oxygenated blood to capillaries, that passively distribute it 
to surrounding organ cells, and veins collect the low oxy-
gen blood, return it to the heart and close the circuit. For a 
long time, blood flow dynamics was considered to be the 
only factor driving arterial-venous specification until genes 
with an arterial-venous-enriched expression pattern started 
to emerge [41]. Mature arteries experience high pulsatile 
shear stress, high blood flow and contain several circum-
ferential and thick layers of smooth muscle cells (SMCs) 
together with extracellular matrix. On the other hand, veins 
experience low shear stress, are covered by significantly less 
SMCs and also have valves to ensure unidirectionality of 
blood flow [42].
Several studies have shown that the first steps of arterial-
venous differentiation occur before significant differences 
in blood flow are experienced by ECs and the current con-
sensus is that ECs become pre-specified to an arterial or 
venous fate before artery or vein assembly, even though this 
process can also be partially modulated by flow. VEGF has 
been shown to be required for the development of arter-
ies through the activation of Dll4/Notch signalling [43, 44]. 
Importantly, the expression of Notch ligands and receptors 
is high in arteries and almost absent in veins [14, 45–47].
Genetic deletion of Dll4 or Notch1 is still compatible 
with the initial development of the first arteries (dorsal 
aorta) but leads to loss of arterial markers (such as those 
encoded by Efnb2, Gja4(Cx37) and Gja5(Cx40)) and wide-
spread expression of venous-related genes [16, 17, 48, 49]. 
The underdeveloped mutant “arteries” have relatively high 
expression of venous-enriched genes (such as EphB4 and 
Flt4). Because of this, it was assumed that the default vas-
cular fate was venous, and that high VEGF/Notch signal-
ling was needed to induce an arterial genetic programme 
on these initially “venous” cells. Questioning the default 
venous fate, was the finding that COUP-TFII is a vein-
specific nuclear receptor that was shown to repress Notch 
during venous specification. Absence of this transcription 
factor leads to the acquisition of arterial identity in venous 
vessels [50]. More recently, COUP-TFII overexpression and 
single-cell RNA sequencing (scRNAseq) studies in coronary 
vessels showed again how the ectopic expression of this fac-
tor blocks arterialization [47]. Importantly, and in contrast 
to previous studies, the authors did not see any significant 
effect of CoupTFIIOE on the expression or activity of Notch 
receptors. Instead, CoupTFIIOE upregulated the expression 
of cell cycle genes. In addition, ectopic Notch activation in 
CoupTFIIOE cells did not rescue their inability to become 
arterial. These results suggest that modulation of the cell 
cycle, not Notch, is the key for the effects of CoupTFII on 
venous development (Fig. 1).
If loss of Notch impairs arterialization, it is expected that 
ectopic activation of Notch signalling induces arterializa-
tion. Indeed, it was shown that during vascular development 
Notch can repress the expression of venous markers in veins 
[51–54]. However, higher resolution mosaic analysis in cor-
onary and retina veins showed that despite the fact that cells 
with higher Notch signaling have a lower tendency to form 
veins, they do differentiate normally, losing the expression 
of arterial marker genes (Cx40) and expressing normal levels 
of EphB4 and CoupTFII [9]. Only in pre-arterial capillar-
ies, cells with high Notch signalling had higher expression 
of arterial marker genes. In pre-venous or venous vessels, 
these cells had normal expression of venous marker genes. 
This study also showed that cells with high Notch prolifer-
ated significantly less, but they differentiated adequately to 
venous cells when located in the right venous microenviron-
ment (Fig. 1).
Even though there are several arterial enriched genes, few 
have such an important role as Notch in arterialization, and 
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For example, Cx37 and Cx40 are excellent markers of the 
arterial phenotype, and strongly activated by Notch, but their 
dual loss do not affect embryonic arterialization. Notch also 
strongly regulates the expression of the arterial-specific 
Ephrin-B2 ligand, and knockout of this ligand also results 
in arterial development defects [55].
Besides the requirement of Notch for the development 
of the dorsal aorta in mouse and zebrafish embryos, its rel-
evance for the development of other arteries has also been 
demonstrated more recently by genetic deletion of Notch 
signalling components in developing coronary, retina and 
brain vessels. The complete loss of Dll4-Notch signalling 
also significantly compromises arterial development in these 
organs [36, 40, 56–58]. This data suggests that most organ 
arteries may require Notch signalling in order to develop. 
Indeed, a recent study using Apelin-driven RbpjKO genetic 
mosaics showed that these cells poorly contribute to the for-
mation of adult aorta, liver, brain, heart and retina arteries 
[9]. However, in these mosaic mutants a significant fraction 
of RbpjKO cells can still form arteries, which raises questions 
about the essential cell-autonomous function of Notch in 
arterialization.
Recent publications using pulse-chase lineage tracing 
genetics in mice or live imaging in zebrafish have provided 
significantly more insight into the process of arterial speci-
fication, and how it involves not only genetic pre-determi-
nation but also mobilization. These studies have shown that 
vein-derived ECs and tip cells with high CXCR4/Notch sig-
nalling migrate against the flow to be incorporated into nas-
cent arteries [59–61]. The concept of arterial development 
accomplished by migratory cells is supported by the pheno-
type resulting from deletion of Cdc42 during retina vascular 
growth. Absence of this small GTPase inhibits EC migration 
and leads to EC accumulation in venous areas [62]. In addi-
tion, recent scRNAseq studies with developing coronary ECs 
collected at different stages showed that there is a continuum 
of EC identities along the arterial-venous axis [47]. A subset 
of endothelial cells go through a gradual switch from a venous-
like programme to a pre-arterial one, well before the main 
coronary arteries form and there is pulsatile flow. Lineage trac-
ing revealed that ECs with high CXCR4, CX40 and Notch 
signalling are more committed/biased to mobilize and form 
arteries. On the contrary, the vein-determining transcription 
factor COUP-TFII suppresses pre-arterial transition by acti-
vating cell cycle genes [47]. This close relationship between 
Fig. 1  Notch signalling regulates arterial specification by inhibiting 
endothelial cell cycle genes and biosynthetic activities. The forma-
tion of arteries and veins was thought to occur by the induction of a 
highly conserved arterial and venous genetic programme in a subset 
of vessels. This specific genetic programme was driven by Notch in 
arteries and COUP-TFII in veins. Contrary to this established model, 
recent findings have suggested that arterial-venous pre-specification 
is tightly linked to the modulation of the endothelial cell cycle and 
this also influences endothelial cell migration/mobilization towards 
arterial or venous vessels. Therefore, the formation of arteries does 
not rely on the direct induction of a Notch-dependent arterial dif-
ferentiation programme, but instead depends on the suppression of 
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veins and cell proliferation and between arrested tip cells and 
arteries seems to be general and is also supported by other 
single-cell transcriptomic and epigenomic studies [63]. In line 
with these results, we have shown recently that it is not the 
Notch-dependent arterial differentiation program, but instead 
the ability of Notch to suppress Myc-dependent endothelial 
metabolism and cell cycle progression, which drives arterial 
mobilization and development [9]. Using standard conditional 
genetics and genetic mosaics we have shown that RbpjKO cells 
rarely form arteries, however Rbpj/MycDKO cells do so equally 
efficiently as wildtype cells. These results show that Notch/
Rbpj signalling does not directly induce arterial specification, 
since it can occur in its absence. Indeed, ectopic activation 
of Notch in different endothelial cell lines is not sufficient to 
arterialize cells [10], even though it biases the cells towards 
arterial mobilization in vivo [9]. Since Myc mainly controls 
cell metabolism and growth, and not directly cell motility, this 
suggests that inhibition of the cell cycle or metabolism by the 
Notch-dependent suppression of Myc may render cells more 
permissive for pre-arterial specification or more chemotac-
tic towards arteries. In line with this, very high VEGF activ-
ity, induced in a mosaic and cell-autonomous manner, also 
decreases EC proliferation and increases the cell´s ability to 
mobilize and form arteries. Most retina Esm1 + tip cells are 
also positive for the cyclin-dependent kinase inhibitor (p21), 
and proliferate significantly less than stalk cells [11], and 
these cells were also shown to effectively mobilize to arteries 
[59–61]. Finally, the use of cell cycle inhibitors during vas-
cular development also enhances arterial specification [47]. 
These studies indicate that arterial-venous pre-specification is 
tightly linked to the modulation of the endothelial cell cycle, 
which also influences EC migration/mobilization towards arte-
rial or venous vessels (Fig. 1). During tissue development, 
this genetic or cell cycle/metabolic specification occurs before 
significant differences in blood flow exist. Nonetheless, blood 
flow and shear stress may help later to reinforce these pre-
existing genetic programs by providing additional biophysi-
cal factors that further enhance the arteriovenous differences. 
Indeed, Notch itself is a mechanosensitive pathway and arterial 
shear stress is able to enhance Notch signalling. This has been 
also shown to supress endothelial proliferation and trigger the 
expression of an arterial-specific program [64–66].
A better understanding of how all these  biophysical 
and genetic factors are spatially and temporally integrated 
in vivo is not only important to gain more knowledge, but 
also because it may allow the development of better thera-
peutic strategies to induce effective arterialization after tis-
sue ischemia, such as after coronary obstruction and myo-
cardial infarction.
Regulation of sprouting angiogenesis by Notch 
signalling
The growth of the vascular network is an extremely dynamic 
process and requires multiple and coordinated steps that 
include EC proliferation, sprouting and migration. When a 
tissue does not have enough oxygen, it secretes pro-angio-
genic factors such as VEGF that, by binding to its recep-
tors, activates a fraction of ECs and confer these a motile 
and invasive phenotype [67–69]. These so-called tip cells 
acquire long filopodia and lead the sprouting process. Fol-
lowing these invasive and migratory cells, are the stalk 
cells, the building blocks for the budding sprout. These cells 
establish a vascular lumen for blood flow and also actively 
proliferate to sustain sprout elongation [70, 71] Most of the 
research done in mice to reveal tip/stalk cell biology has 
been performed in the postnatal mouse retinal angiogen-
esis model, which is a relatively easy system to genetically 
manipulate and image [72]. Using this system it has been 
shown that the biology of tip and stalk cells is strongly regu-
lated by the VEGF/Notch pathway [69, 73]. VEGF is one 
of the most potent pro-angiogenic factors and its blockade 
results in severe retinal angiogenesis defects, with a marked 
decrease in the number of sprouting cells [40, 74]. VEGF 
gradient and concentration finely regulate tip cell migration 
and stalk cell proliferation [67]. Mechanistically, VEGF-
induced VEGFR2 signalling triggers several phosphoryla-
tion cascades, including the downstream mitogen-activated 
protein kinase (MAPK)/ extracellular signal regulated kinase 
(ERK) signalling activation [75, 76]. In addition, VEGFR2 
signalling leads to the transcription of tip cell-enriched 
genes such as Esm1 and Dll4. Tip cells that express more 
Dll4, in turn activate Notch signalling in the adjacent cells. 
Consequently, this maintains the stalk fate in adjacent cells 
by suppressing tip cell behaviour [21, 22, 36, 37]. Dele-
tion of just one Dll4 allele is sufficient to induce excessive 
sprouting and vessel branching because of increased tip cell 
formation. This is accompanied by an increase in tip cell-
enriched genes such as PdgfB, Unc5b [38], Esm1, or Apln 
[77] in the rest of the vasculature. Loss of Notch signalling 
by deleting Dll4, Notch1 or Rbpj leads to pronounced vas-
cular developmental defects that were initially related with a 
general increase in EC activity and angiogenesis [16, 21, 22, 
36–39]. Conversely, Notch gain-of-function studies showed 
that it decreases vascular density and reduced tip cell num-
ber and EC sprouting [38, 78, 79]. Manipulation of Notch 
signalling activity in a mosaic manner confirmed the role 
of Notch signalling in tip cell specification [36, 75]. Live 
imaging and fate-mapping studies in zebrafish and mouse 
models have shown that tip cell specification is likely tran-
sient and oscillatory, since ECs can switch between stalk 
and tip positions during angiogenesis. This dynamic process 
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and Notch signalling levels, which drive a continuous shuf-
fling of tip and stalk cells competing for the lead position 
[80, 81]. Since in other developmental systems Notch has 
been shown to be activated in an oscillatory manner [82], 
oscillations in the levels of Notch signalling may be also 
involved in the regulation of the observed oscillatory tip/
stalk cell fates and dynamics. In addition, signaling through 
bone morphogenetic proteins and SMAD1/5 [83–85], and 
remodelling of VE-cadherin junctions [86] have also been 
shown to be involved in tip/stalk cell interconversion, and 
these molecular mechanisms can also be regulated upstream 
by Notch/Heys and VEGF signalling. Furthermore, ECs, and 
particularly tip cells, have been shown to polarize against 
blood flow and form the source for arterial development, 
both in the mouse retina and in zebrafish [59, 60, 87]. Nev-
ertheless, only a fraction of them seem to be able to do so, 
as most Esm1 + tip cells pulse-chased at postnatal day 3 (P3) 
have not incorporated into arteries at P6 [11] (Fig. 2).
The potent effect of Dll4/Notch as a suppressor of 
sprouting angiogenesis was also shown in pathological 
conditions. Dll4/Notch inhibition resulted in a significant 
decrease in tumour growth due to excessive but non-pro-
ductive sprouting angiogenesis [21, 22]. The paradoxal 
reduction in tumour growth by Notch blockade, even after 
triggering an increase in sprouting angiogenesis, was 
explained by the authors as a consequence of a decrease 
in tumour blood perfusion when vessels are excessively 
branched.
In addition to Dll4, another Notch ligand was found to 
have an important and opposing role in tip/stalk cell biology 
and angiogenesis. Jagged1 was found to be a pro-angiogenic 
regulator mainly expressed in stalk cells which antagonizes 
Fig. 2  ECs have a bell-shaped dose-dependent response to mitogenic 
stimuli in vivo. By binding to its cognate receptor VEGFR2, VEGF 
activates the fraction of ECs that become leading tip cells, trigger-
ing several downstream cascades, including the MAPK/ERK signal-
ling pathway. These high VEGF/ERK signalling cells also express 
p21, which results in an arrested and non-proliferative EC pheno-
type. VEGFR2 signalling also results in Dll4 expression on tip cells, 
which in turns activates Notch signalling in the adjacent stalk cells 
and suppresses the tip cell phenotype by downregulating ERK sig-
nalling. Therefore, physiological Notch signalling in stalk cells is 
essential to prevent the hypermitogenic arrest of these ECs and sus-
tain angiogenesis. Overall, recent studies have shown that adequate 
VEGF and Notch signalling balance must be maintained in order for 
ECs to proliferate and sprout/migrate adequately. Jagged1 is a pro-
angiogenic regulator mainly expressed in stalk cells which antago-
nizes Dll4-Notch signalling from stalk cells to tip cells. Contrary 
to previous studies, it has been shown that tip cells express similar 
amounts of VEGFR2 protein as stalk cells but they have higher ERK 
activity, likely because of their high proximity to the VEGF source 
and lower Notch activity. Tip cell specification has been shown to be 
transient and oscillatory. ECs at the leading edge are exposed to vary-
ing growth and biophysical factors, which makes them having differ-
ent abilities to compete for the tip position. This continuous sensing 
and reaction to the surrounding tissue microenvironment results in a 
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Dll4-Notch signalling in Fringe glycosyltransferases (Mfng/
Lfng) expressing ECs, including tip cells [39]. By glyco-
sylating the Notch receptors, Fringes polarize the function of 
the Delta and Jagged ligands [88, 89] in ECs. In the presence 
of glycosylated Notch receptors, Delta becomes a stronger 
ligand while Jagged becomes a weaker ligand, but since both 
bind the same receptors, Jagged1 reduces endothelial Dll4/
Notch signalling. Therefore, the relative expression of and 
equilibrium between different Notch ligands and modula-
tors control and reinforce the different behaviours between 
endothelial tip cells (Notch signalling sending) and stalk 
cells (Notch signalling receiving cells) (Fig. 2).
For many years, the VEGF/Notch interplay in tip/stalk 
cell differentiation was thought to rely on the suppression 
of VEGFR2 transcription by Dll4-Notch activation in stalk 
cells, which was shown to happen in cultured HUVECs [69, 
90, 91]. However, several other studies showed that Notch 
does not significantly regulate the transcription of Vegfr2 in 
vivo in retina, heart and zebrafish vessels [9, 11, 37, 40, 92] 
and that tip cells express similar amounts of Vegfr2 protein 
as stalk cells [40]. These studies also showed that unlike 
Vegfr2, Vegfr3 transcription and protein levels are more 
tightly regulated by Notch signalling in vivo, however this 
receptor does not bind VEGF-A (only VEGF-C/D) and its 
role is more important for lymphangiogenesis (Adams et al., 
2007), even though it can also heterodimerize with VEGFR2 
and potentially regulate its function [74]. Nonetheless, all 
available evidence shows that tip cells have higher MAPK/
ERK activity, which is strongly activated by VEGF signal-
ling and suppressed by Notch signalling [11, 76]. Tip cells 
have relatively higher ERK activity, likely because of the 
combination of two factors, being the higher proximity to 
the VEGF source, and the lower Notch signalling activity. 
The latter could be due to Dll4 cis-Notch signalling inhi-
bition in tip cells plus the weaker expression of Dll4 (and 
stronger Jagged1) ligands by stalk cells. Demonstrating the 
key role of ERK activity in tip cell biology, suppression 
of MEK/ERK signalling with pharmacological compounds 
completely prevents EC sprouting or migration in zebrafish 
and in the retinal angiogenesis model [11, 76].
Given that tip cells have higher MEK/ERK activity, one 
would expected these to proliferate more than stalk cells. 
However, in vivo studies have shown that retina tip cells, 
particularly VEGF/Esm1-high tip cells, are less prolifera-
tive than their neighbouring stalk cells [11, 67]. A recent 
study has shown that ECs have a bell-shaped dose-dependent 
response to mitogenic stimuli in vivo [11]. When mitogenic 
stimulation is increased by Dll4/Notch signalling inhibition, 
or by VEGFR2 signalling overactivation, the most angio-
genic and proliferative ECs located at the angiogenic front 
exit the cell cycle. Although in the first 24 h ECs subjected 
to loss of Notch signalling experience a transient increase 
in the speed of cell cycle progression and division, this is 
followed by a pronounced cell cycle arrest at 48 h after the 
start of the inhibition. This arrest is partially mediated by 
the strong upregulation of ERK activity and p21. Therefore, 
even though Notch overactivation does block endothelial cell 
proliferation, physiological Notch signalling does not inhibit 
angiogenesis but is instead essential to prevent the arrest of 
endothelial stalk cells at the angiogenic vascular front, thus 
sustaining angiogenesis [11]. During physiological retinal 
angiogenesis, higher ERK signalling and p21 expression 
(inducing cell cycle arrest) is restricted to tip ECs, being 
the cells with lower Notch signalling and higher VEGF sig-
nalling. The cell cycle arrest of tip cells is likely necessary 
to enhance their sprouting/migration ability. These studies 
also show that an adequate VEGF and Notch signalling 
balance must be maintained in order for ECs to prolifer-
ate and sprout/migrate adequately. These results may also 
partially explain the failure of therapeutic pro-angiogenic 
strategies, such as the delivery of growth factors after myo-
cardial infarction [93, 94]. This simple approach is likely not 
enough to effectively stimulate angiogenesis since vessels 
elicit cell cycle checkpoint mechanisms at high levels of 
growth factor stimulation. Understanding these hypermi-
togenic arrest mechanisms in more detail may shed more 
light on ways of effectively boosting therapeutic angiogen-
esis (Fig. 2).
Role of Notch in vascular maturation and quiescence
After the angiogenic expansion of the blood vessel network, 
vessels undergo maturation in order to form a functional 
vascular system. This maturation includes vascular pruning, 
remodelling, stabilization and finally cellular differentiation, 
and culminates with the acquisition of a quiescent state [42, 
71]. During the process of vascular maturation, there is a 
progressive switch from active growth to a quiescent state. 
This switch relies mostly on the withdrawal of pro-angio-
genic microenvironmental cues but also cell-intrinsic and 
cell-to-cell contact molecular mechanisms [95]. This leads 
to a significant decrease in endothelial proliferation and the 
markers of angiogenic activity or sprouting. Most quiescent 
ECs do not proliferate and have a very low metabolic and 
gene expression profile. Quiescence is however a reversible 
state. The quiescent phenotype is in general maintained until 
ECs detect pro-angiogenic signals that can rapidly switch 
them from a long-term quiescence to an active growth state 
[71]. In an adult organism, the maintenance of a quiescent 
and functional vascular network is critical for the struc-
ture and function of organ parenchyma, maintaining tissue 
homeostasis. It is also becoming clear that maintenance of 
vascular quiescence and homeostasis is not a passive pro-
cess, but involves the activity of several signalling pathways, 
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Many signalling pathways required for the development 
of blood vessels have been associated with the vascular mat-
uration process, and the recruitment of endothelial support-
ing cells, including pericytes and vascular smooth muscle 
cells (VSMCs), has been shown to stabilize nascent blood 
vessels and regulate the secretion of important extracellular 
matrix components [67, 96, 97].
Besides the essential role of Notch during vasculogenesis 
and angiogenesis, it has been shown that Notch signalling 
it is also required throughout the entire vascular maturation 
process. In the mouse retina model, it has been shown that 
Dll4-Notch signalling activity is essential for the pruning 
and maturation of veins and perivenous capillaries, but sur-
prisingly not for the maintenance of arteries [78]. Endothe-
lial-specific deletion of Rbpj leads to reduced vessel prun-
ing and mural cell recruitment, with an increase in vessel 
sprouting and proliferation only in the venous areas. Despite 
the Notch pathway components being highly expressed in 
the arterial endothelium throughout life, they do not seem 
to have a major function in their homeostasis [78]. Loss 
of Notch1 in aorta endothelial cells results in a very mild 
increase in EC proliferation [65]. In contrast to angiogenic 
ECs, loss of Dll4/Notch signalling in the maturing vascular 
plexus of the retina leads to cell cycle reentry [78], instead 
of cell cycle exit, which is likely due to the lower basal levels 
of VEGF/mitogenic stimuli in maturing/remodelling vessels 
and the identified bell-shaped dose-dependent response to 
mitogenic stimulation [11]. This highlights once again how 
much the role of Notch and VEGF in EC biology depend on 
mitogenic context.
Several studies also showed that the Notch signalling 
pathway is essential to maintain the quiescence of some 
organ vessels and their homeostasis. Pharmacological inhi-
bition or genetic deletion of different Notch components 
such as Dll4, Notch1, or Rbpj in the adult and fully mature 
endothelium results in enlarged vessels and increased vascu-
lar density and in some studies this was linked to an increase 
in EC proliferation and vascular neoplasms [15, 98–101]. 
Overall, these studies raised important concerns against 
the use of Notch inhibitors in the clinics and questioned 
the safety of targeting the Dll4-Notch1 signalling axis. Tar-
geting this signalling pathway was before seen as a very 
promising approach against cancer, since Dll4 blockade with 
Dll4-Fc or anti-Dll4 monoclonal antibodies significantly 
reduced tumour growth, even in tumours resistant to anti-
VEGF treatment [21, 22]. Now, these more recent studies 
on the effect of Notch blockers in vascular quiescence reveal 
potential secondary effects of those treatments and raise a 
red flag in the use of anti-Dll4/Notch for cancer treatment. 
Other studies suggested that the anti-Dll4/Notch effects on 
quiescent vessels are reversible after treatment withdrawal 
and may have less impact on organ physiology than initially 
proposed [102].
The mechanisms triggered by Notch activation that 
induce EC quiescence are still incompletely understood. 
Mechanisms identified by overactivation of Notch signal-
ling in cultured cells may also be misleading, since the 
range of genetic targets activated by Notch signalling is 
dose-dependent and not easily modelled in gain-of-func-
tion assays, particularly in vitro. Nonetheless, several 
factors downstream of Notch have been suggested to be 
responsible for inducing EC quiescence by repressing pro-
liferation both in vitro and in vivo, such as Interleukin-33, 
p27, thrombospondin-1, p21 and PTEN [103–106]. Alto-
gether, these studies point to Notch activation being a pro-
quiescence pathway that is essential to maintain vascular 
homeostasis [15, 98–101].
Some other studies have linked the role of Notch in vascu-
lar quiescence with shear stress. These studies suggested that 
vascular quiescence is a blood flow or shear stress-dependent 
process, which is mediated by Notch-mediated suppression 
of the cell cycle and the stabilization of cell-to-cell contact 
mechanisms. These studies proposed that Notch signalling 
activity is regulated by shear stress not only during arterial 
development but also during adult arterial homeostasis [65, 
66]. Surprisingly, a non-canonical and transcriptional-inde-
pendent Notch-mediated mechanism was also proposed to be 
involved in endothelial barrier maintenance by Notch. Shear 
stress promotes Dll4-dependent proteolytic cleavage of the 
Notch transmembrane domain, which increases its avail-
ability to complex with other proteins as VE-cadherin, and 
the Rac1 guanidine-exchange factor TRIO. This complex 
allows to control adherens junctions and barrier function 
independently of the role of Notch signaling in transcrip-
tional regulation [107].
Role of Notch in cardiovascular disease
The role of Notch in the adult vasculature after induced 
cardiovascular disease was also analysed. In the hindlimb 
ischemia model, Dll1 haploinsufficieny impairs arterial 
remodelling and blood flow restoration. Dll1 expression is 
restricted to arterial endothelium and its upregulation seems 
to be required for the Notch-dependent arteriogenesis [108]. 
In line with this, Notch1 and Notch4 have also been shown 
to be required for proper angiogenesis and blood flow recov-
ery in hindlimb ischemia models [109]. In another study, 
Dll4 heterozygous mice were found to have more pial col-
lateral arteries and have reduced blood flow conductance 
after femoral artery occlusion. Despite markedly increased 
angiogenesis, tissue ischemia was more severe in these mice 
[110].
The role of Notch signalling in atherosclerosis has also 
been evaluated. Some reports have shown that endothelial 
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decreased secretion of inflammatory factors and leukocyte 
recruitment [111]. In contrast, others studies have suggested 
an atheroprotective role for Notch signalling and increased 
expression of pro-inflammatory genes in the absence of 
Notch1 [65]. Despite these opposing results, and diversity 
of the proposed mechanisms, endothelial Notch signalling 
seems to be very relevant for cardiovascular disease and 
future studies will refine its role in these processes.
Angiocrine functions of endothelial Notch signalling
Apart from the widely known function of blood vessels in 
delivering oxygen and nutrients, ECs are also involved in the 
control of an extensive variety of other physiological pro-
cesses. Some of these important EC roles rely on the expres-
sion and secretion of either stimulatory or inhibitory growth 
factors, morphogens or chemokines, popularly referred as 
angiocrine factors. It has been shown that these endothelial 
secreted factors are able to regulate the homeostasis, self-
renewal, growth and differentiation of neighboring cells or 
resident stem cells [112]. Although Aristotle already sug-
gested an essential role of vascular structures during organo-
genesis [113], it was shown approximately 20 years ago that 
liver sinusoidal ECs were involved in liver bud development 
in a perfusion-independent manner [114]. Since then, many 
studies have listed genes expressed by ECs, which can code 
for potential angiocrine factors. Among those signals, Notch 
was proposed to be such an angiocrine factor for its ability 
to transmit signals by cell-to-cell contact.
One of the first results showing an angiocrine role for 
endothelial Notch was obtained by analysing the role of 
the Notch pathway in the bone marrow endothelium and 
associated hematopoiesis. It was found that upon myeloab-
lation, ECs from the bone marrow niche are able to support 
the self-renewal of the hematopoietic stem cell (HSC) pool 
through expression of the Jagged1 and Jagged2 ligands and 
subsequent Notch activation in HSCs [115, 116]. Later it 
was also found that in steady-state conditions, endothelial 
expression of Dll1 in the bone marrow and spleen regulates 
monocyte fate, favouring the conversion of  Ly6Chi mono-
cytes into  Ly6Clow monocytes. However, during ischemia, 
Dll1 upregulation in arterial ECs leads instead to differen-
tiation of  Ly6Chi monocytes into macrophages that promote 
arteriogenesis and allow tissue repair [117, 118]. It was also 
found in the bone marrow that endothelial Notch signalling 
induces the expression and secretion of the angiocrine fac-
tor Noggin. This bone morphogenic protein is required for 
chondrocyte and osteoblast homeostasis [119].
Notch activation can also be detrimental for the homeo-
stasis or biology of the surrounding tissue. Notch activation 
in sinusoidal liver ECs downregulates important hepatocyte 
mitogens such as Wnt2, Wnt9b and hepatocyte growth fac-
tor [120]. This leads to impaired hepatocyte proliferation 
not only during organ homeostasis but also in regenerating 
conditions.
It was also shown in liver that mechanically stretched 
sinusoidal ECs upregulate Cxcl1 via Notch. The secretion 
of this angiocrine factor leads to neutrophil recruitment 
and subsequent formation of neutrophil extracellular traps 
with microthrombi [121]. Moreover, it has been shown that 
high levels of VEGFR2/Notch signalling in ECs results in 
myocardial hypertrophy. An increase of endothelial VEGF/
VEGR2 signalling leads to Notch activation in ECs, which 
results in increased expression of Adam12 and Klk8. The 
upregulation of these two genes allows the release of the 
heparin-binding-EGF and neuregulin1 ligands by ECs, 
which promote their binding to ErbB receptors in neighbour-
ing cardiomyocytes, and consequently enhance their growth 
[122]. Repetitive lung injury was also shown to result in 
the upregulation of Jag1 by endothelial cells. This ligand 
activates Notch signalling in perivascular fibroblasts and 
consequently enhances fibrosis [123].
A comprehensive knowledge of the organ-specific angi-
ocrine functions by Notch is required to understand and pre-
dict the impact of pharmacological targeting of this pathway 
in translational vascular medicine. The promising therapeu-
tic potential of tissue-specific and resident ECs may repre-
sent a target for angiocrine-mediated tissue regeneration/
biology, or for the amelioration of certain conditions such 
as fibrosis [112].
Role of Notch on vascular heterogeneity arising 
from single‑cell studies
Recent scRNA-seq studies have allowed the comparative 
analysis of the transcriptome of most ECs within most adult 
organ vascular beds [63, 124–133].
Bioinformatics analyses of single-cell experiments were 
used to study the differentiation of different endothelial cell 
types during vascular development. An elegant scRNA-seq 
study on developing heart vessels showed that venous cells 
go through a gradual switch from a venous programme to 
an arterial one characterized by higher Notch activity and 
expression of target genes (Efnb2, Hes1, Hey2, Gja5 and 
Gja4) during heart development [47]. Analysis of adult 
organ vessels has also revealed that there is a continuum 
of Notch-related single endothelial cell identities along the 
arterial-venous axis [14, 63, 133].
In the liver it was also found that this arterial-venous 
vascular continuum correlated with the surrounding tis-
sue spatial heterogeneity or zonation. By combining sin-
gle-molecule in situ hybridization, scRNA-seq and paired-
cell sequencing, recent studies spatially reconstructed the 
endothelial-hepatocyte zonation [134, 14]. Interestingly, 
the spatial zonation related with Notch signalling follows 
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are highly expressed in the oxygenated portal nodes, which 
comprise the hepatic arteries and portal veins. Notch expres-
sion and activity progressively decreases continuously in 
capillaries towards the hepatic central veins [14]. Given the 
role of Notch as a master regulator of cellular and transcrip-
tional heterogeneity it will be interesting to know its role 
in the specification of this arterial-venous diversity at the 
single-cell level in different adult organ vascular beds.
Conclusions
In the last years there has been a substantial progress in 
the understanding of Notch signalling in endothelial cell 
proliferation, sprouting, migration, vessel stabilization and 
maturation. Both in vitro and in vivo studies have shown 
how the spatial and temporal-context of an endothelial cell, 
strongly influences the role of Notch on its specification, 
proliferation and homeostasis. Dispite significant progress, 
still little is known about the complex genetic programmes 
triggered by Notch that support these context-dependent dif-
ferences. Future single-cell and genetic studies and related 
breakthrough technologies will certainly expand our under-
standing of how Notch controls endothelial heterogeneity 
in different organs and tissues during development, homeo-
stasis and disease. The challenge will be to integrate the 
immense datasets that will be generated and functionally 
validate the therapeutic relevance of those findings. 
While the induction of therapeutic angiogenesis may be 
advantageous in cardiovascular diseases such as heart and 
brain ischemia, hypovascular-related dementia, neurode-
generation and wound healing, its inhibition would be ben-
eficial in inflammatory disorders, diabetes and cancer [1, 
3]. Even though targeting Notch signalling as a whole is not 
as vascular-specific as targeting VEGF signalling, it is still 
one of the most important pathways for vascular biology 
and homeostasis. In a adult organism, Dll4 (and Notch4) is 
mainly expressed by ECs, and therefore it is still an attrac-
tive vascular-specific therapeutic target, particularly if issues 
related with the induction of vascular neoplasms after its 
inhibition in quiescent vessels are resolved. Future studies 
may identify ways to interfere specifically with the Dll4/
Notch function during angiogenesis without compromising 
its protective role on vascular homeostasis.
Therefore, a better understanding of the mechanisms that 
control angiogenesis versus vascular homeostasis may be of 
high therapeutic relevance. This may lead to the identifica-
tion of treatments with higher biomedical precision and less 
undesired side effects.
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